Examination of smears for tubercle bacilli by Fluorescence Microscopy

IN underdeveloped countries, laboratory facilities for the bacteriological diagnosis of tuberculosis are at present, very limited. Cultural methods are unlikely to be used on a large scale for many years to come. It is, therefore, important to investigate the most economical method of examining smears for tubercle bacilli. Fluorescence microscopy was introduced by Hagemann (1937) and has since been described by many authors, including Tanner (1941, 1948), Lind and Shaughnessy (1941), Lempert (1944), Norman and Jelks (1945), Clegg and Foster-Carter (1946), Wilson (1952), Von Haebler and Murray (1954), and Needham (1957). The great advantage claimed for this method is that stained bacilli can be detected using a much lower magnification than with the usual Ziehl-Neelsen method. Considerable time is saved in examining smears and larger areas can be searched. The method has not been widely employed for two reasons. In the first place, the light source must be very bright and many of the optical systems described previously have only supplied sufficient light if the equipment was used in a darkened room. Secondly, some workers (Ritterhoff and Bowman, 1945; Kuster, 1939; Holm and Plum, 1943) consider that false positive results can be obtained, since some smears may contain small naturally fluorescent particles which can be confused with bacilli. Equipment for fluorescence microscopy that can be used in normal daylight has been in use at the Tuberculosis Chemotherapy Centre, Madras, for over two years. When it was first introduced, a comparison between this method and the conventional Ziehl-Neelsen method was undertaken to test their relative sensitivities, and to see whether fluorescence microscopy yielded false positive results. The results of this comparison are described

Bound states near a moving charge in a quantum plasma

It is investigated how the shielding of a moving point charge in a one-component fully degenerate fermion plasma affects the bound states near the charge at velocities smaller than the Fermi one. The shielding is accounted for by using the Lindhard dielectric function, and the resulting potential is substituted into the Schr\"odinger equation in order to obtain the energy levels. Their number and values are shown to be primarily determined by the value of the charge and the quantum plasma coupling parameter, while the main effect of the motion is to split certain energy levels. This provides a link between quantum plasma theory and possible measurements of spectra of ions passing through solids.Comment: Published in EPL, see http://epljournal.edpsciences.org/articles/epl/abs/2011/09/epl13478/epl13478.htm

Whole-blood transcriptomic signatures induced during immunization by chloroquine prophylaxis and Plasmodium falciparum sporozoites

A highly effective vaccine that confers sterile protection to malaria is urgently needed. Immunization under chemoprophylaxis with sporozoites (CPS) consistently confers high levels of protection in the Controlled Human Malaria infection (CHMI) model. To provide a broad, unbiased assessment of the composition and kinetics of direct ex vivo human immune responses to CPS, we profiled whole-blood transcriptomes by RNA-seq before and during CPS immunization and following CHMI challenge. Differential expression of genes enriched in modules related to T cells, NK cells, protein synthesis, and mitochondrial processes were detected in fully protected individuals four weeks after the first immunization. Non-protected individuals demonstrated transcriptomic changes after the third immunization and the day of treatment, with upregulation of interferon and innate inflammatory genes and downregulation of B-cell signatures. Protected individuals demonstrated more significant interactions between blood transcription modules compared to non-protected individuals several weeks after the second and third immunizations. These data provide insight into the molecular and cellular basis of CPS-induced immune protection from P. falciparum infection

Six simple guidelines for introducing new genera of fungi

We formulate five guidelines for introducing new genera, plus one recommendation how to publish the results of scientific research. We recommend that reviewers and editors adhere to these guidelines. We propose that the underlying research is solid, and that the results and the final solutions are properly discussed. The six criteria are: (1) all genera that are recognized should be monophyletic; (2) the coverage of the phylogenetic tree should be wide in number of species, geographic coverage, and type species of the genera under study; (3) the branching of the phylogenetic trees has to have sufficient statistical support; (4) different options for the translation of the phylogenetic tree into a formal classification should be discussed and the final decision justified; (5) the phylogenetic evidence should be based on more than one gene; and (6) all supporting evidence and background information should be included in the publication in which the new taxa are proposed, and this publication should be peer-reviewed

Shielding of a moving test charge in a quantum plasma

The linearized potential of a moving test charge in a one-component fully degenerate fermion plasma is studied using the Lindhard dielectric function. The motion is found to greatly enhance the Friedel oscillations behind the charge, especially for velocities larger than a half of the Fermi velocity, in which case the asymptotic behavior of their amplitude changes from 1/r^3 to 1/r^2.5. In the absence of the quantum recoil (tunneling) the potential reduces to a form similar to that in a classical Maxwellian plasma, with a difference being that the plasma oscillations behind the charge at velocities larger than the Fermi velocity are not Landau-damped.Comment: 9 pages, 11 figures. v3: Fixed typo, updated abstrac

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy

Purpose of the study: Pregnant women experience physiological changes during pregnancy resulting in clinically significant alterations in antiretroviral pharmacokinetics (PK). Therefore, achieving and maintaining optimal plasma concentrations of antiretroviral drugs is essential for maternal health and minimising the risk of mother-to-child transmission of HIV. The aim of this study is to describe atazanavir/ritonavir (ATV/r) PK during pregnancy. Methods: Pregnant HIV-positive women received ATV/r as part of their routine pre-natal care. Demographic and clinical data were collected, and ATV plasma concentrations [ATV] were determined in the first (T1), second (T2) and third (T3) trimester using HPLC-MS/MS (LLQ=0.05 µg/mL). Postpartum (PP) sampling was performed where applicable. Antepartum (AP) and PP PK parameters were compared using a one-way ANOVA. Summary of results: From January 2007, 44 women (37 black African) were enrolled in the study. All received ATV/r at a standard dose of 1 tablet once daily (300/100 mg od). 24 women were receiving ART prior to pregnancy, and 20 women initiated ATV/r during pregnancy. Median (range) gestation at treatment initiation in these patients was 23.5 weeks (7–35). At the time nearest to delivery 31 patients had an undetectable plasma viral load (pVL), 6 patients had detectable pVL and 2 were unavailable. [ATV] were determined in 11/44 (T1); 25/44 (T2); 35/44 (T3) and 28/44 (PP) patients. Time of TDM sampling, gestation time and [ATV] (geometric mean; 95% CI) are given in the Table. 6 patients were either below or approaching the ATV MEC (0.15 µg/mL) during pregnancy; of these, 4/6 achieved undetectable pVL at the time of delivery (1=pVL of 291 copies/mL; 1 unavailable). [ATV] were significantly lower at T2/T3 relative to T1/PP. Equally, in a paired analysis of 28 patients (T2/T3 vs. PP), [ATV] were significantly reduced at T2/T3 (P=0.003). Conclusions: This study represents one of the larger cohorts of women undergoing TDM for ATV in pregnancy. Lower [ATV] were seen in T2 and T3 when compared to T1. However, such findings were not associated with viral breakthrough or HIV transmissions. Nonetheless, careful monitoring of women in pregnancy is required, and if there is concern for inadequate levels, dose adjustment of ATV upward from 300 mg to 400 mg may be an option